Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 111-122
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2221-2232
Open Access | Times Cited: 1015
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 211
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Donna H. Ryan, Ildiko Lingvay, John Deanfield, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2049-2057
Open Access | Times Cited: 78
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 58
Obesity in adults
Ildiko Lingvay, Ricardo V. Cohen, Carel W. le Roux, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 972-987
Closed Access | Times Cited: 52
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M. Scirica, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 773-786
Open Access | Times Cited: 43
Contemporary pharmacological treatment and management of heart failure
Biykem Bozkurt
Nature Reviews Cardiology (2024) Vol. 21, Iss. 8, pp. 545-555
Closed Access | Times Cited: 24
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 19
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1632-1642
Open Access | Times Cited: 18
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Ildiko Lingvay, John Deanfield, Steven E. Kahn, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1360-1369
Open Access | Times Cited: 17
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Steven E. Kahn, John Deanfield, Ole K. Jeppesen, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1350-1359
Open Access | Times Cited: 16
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Emily R. Hankosky, Hui Wang, Lisa M. Neff, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 319-328
Open Access | Times Cited: 34
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 26
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity
Amgad Mentias, Milind Y. Desai, Ali Aminian, et al.
Circulation Heart Failure (2024) Vol. 17, Iss. 2
Closed Access | Times Cited: 13
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review
Alexandre Dréant, Claire Blanchard, David Jacobi
Obesity Surgery (2024) Vol. 34, Iss. 5, pp. 1846-1854
Closed Access | Times Cited: 8
Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum
Izza Shahid, Muhammad Shahzeb Khan, Javed Butler, et al.
Heart Failure Reviews (2025)
Closed Access | Times Cited: 1
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Robert F. Kushner, Donna H. Ryan, John Deanfield, et al.
Obesity (2025)
Open Access | Times Cited: 1
Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Eon Ju Jeon, Kiyoung Lee, Kyoung Kon Kim
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 2, pp. 106-120
Open Access | Times Cited: 21
The cardiovascular effects of novel weight loss therapies
Muhammad Usman, Melanie J. Davies, Michael E. Hall, et al.
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5036-5048
Closed Access | Times Cited: 17
Semaglutide: a new drug for the treatment of obesity
Joel Lexchin, Barbara Mintzes
Drug and Therapeutics Bulletin (2023) Vol. 61, Iss. 12, pp. 182-188
Closed Access | Times Cited: 16
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Mariam M. Ali, Sanober Parveen, Vanessa Williams, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100341-100341
Open Access | Times Cited: 7
Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective
Anamaria‐Vera Olivieri, Sergey Muratov, Sára Larsen, et al.
International Journal of Obesity (2024) Vol. 48, Iss. 5, pp. 683-693
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top